Excalipoint Therapeutics Announces Clinical Trial Collaboration with Roche to Evaluate EXP011 in DLL3-Positive Solid Tumors
We are excited to announce that our portfolio company, Excalipoint Therapeutics, has entered into a clinical trial collaboration with Roche. Under this agreement, Roche will provide atezolizumab (Tecentriq®) to evaluate the combination potential of Excalipoint's lead asset, EXP011 (CTM012) , in DLL3-positive solid tumors.
EXP011 is a tri-specific T cell engager targeting DLL3, CD3, and 4-1BB, developed on Excalipoint's proprietary EXCOPIA™ co-stimulatory platform (formerly TOPAbody). The initial study will focus on small cell lung cancer (SCLC) , with plans to expand into neuroendocrine tumors (NET) and other DLL3-expressing malignancies.
Management Commentary
Dr. Lei Fang, Co-Founder, Chairman, and CEO of Excalipoint, commented:
"We are pleased to collaborate with Roche to explore the therapeutic potential of combining EXP011 with atezolizumab for patients with SCLC and other difficult-to-treat solid tumors. This collaboration allows us to evaluate a differentiated immuno-oncology combination strategy designed to overcome the limitations of current treatment options and deliver better clinical outcomes for patients."
Mr. Jielun Zhu, Co-Founder, CFO, and CBO of Excalipoint, added:
"This clinical collaboration with Roche further underscores the clinical value of EXP011 in solid tumors and accelerates the global development of this highly differentiated asset. The partnership is a strong validation of EXP011's potential to break through existing therapeutic barriers, achieve more durable responses, and improve patient outcomes."
Strategic Significance
This collaboration marks another major milestone for Excalipoint, following its $68.7 million seed financing (one of the largest seed rounds in China biotech history). Roche's PD-L1 inhibitor has become a common combination partner in DLL3-targeted immuno-oncology research, with similar clinical supply agreements recently established with companies like Phanes Therapeutics.
DLL3, a tumor-specific antigen highly expressed in SCLC and neuroendocrine tumors, has emerged as a key therapeutic target. As one of the few DLL3×CD3 bispecific/trispecific antibodies currently in clinical development, EXP011's differentiated design incorporates a 4-1BB co-stimulatory signal, potentially enabling more durable and deeper anti-tumor responses compared to approved DLL3-targeting therapies.
CO-WIN VENTURES' Perspective
As an early investor since Excalipoint's founding round, CO-WIN VENTURES has been privileged to witness the company's rapid evolution. From its $41 million founding round in August 2025 to achieving clinical proof-of-concept and now securing a collaboration with Roche—all within an exceptionally short timeframe—the Excalipoint team has demonstrated outstanding execution and scientific rigor.
This collaboration with Roche represents a strong endorsement from a global pharmaceutical leader of Excalipoint's differentiated TCE platform and pipeline. The combination of T cell engagers with immune checkpoint inhibitors holds the potential to unlock greater therapeutic efficacy in solid tumors.
We look forward to EXP011's continued clinical progress and its potential to deliver breakthrough treatment options for cancer patients worldwide.
Congratulations to the entire Excalipoint team!
EXP011 is a tri-specific T cell engager targeting DLL3, CD3, and 4-1BB, developed on Excalipoint's proprietary EXCOPIA™ co-stimulatory platform (formerly TOPAbody). The initial study will focus on small cell lung cancer (SCLC) , with plans to expand into neuroendocrine tumors (NET) and other DLL3-expressing malignancies.
Management Commentary
Dr. Lei Fang, Co-Founder, Chairman, and CEO of Excalipoint, commented:
"We are pleased to collaborate with Roche to explore the therapeutic potential of combining EXP011 with atezolizumab for patients with SCLC and other difficult-to-treat solid tumors. This collaboration allows us to evaluate a differentiated immuno-oncology combination strategy designed to overcome the limitations of current treatment options and deliver better clinical outcomes for patients."
Mr. Jielun Zhu, Co-Founder, CFO, and CBO of Excalipoint, added:
"This clinical collaboration with Roche further underscores the clinical value of EXP011 in solid tumors and accelerates the global development of this highly differentiated asset. The partnership is a strong validation of EXP011's potential to break through existing therapeutic barriers, achieve more durable responses, and improve patient outcomes."
Strategic Significance
This collaboration marks another major milestone for Excalipoint, following its $68.7 million seed financing (one of the largest seed rounds in China biotech history). Roche's PD-L1 inhibitor has become a common combination partner in DLL3-targeted immuno-oncology research, with similar clinical supply agreements recently established with companies like Phanes Therapeutics.
DLL3, a tumor-specific antigen highly expressed in SCLC and neuroendocrine tumors, has emerged as a key therapeutic target. As one of the few DLL3×CD3 bispecific/trispecific antibodies currently in clinical development, EXP011's differentiated design incorporates a 4-1BB co-stimulatory signal, potentially enabling more durable and deeper anti-tumor responses compared to approved DLL3-targeting therapies.
CO-WIN VENTURES' Perspective
As an early investor since Excalipoint's founding round, CO-WIN VENTURES has been privileged to witness the company's rapid evolution. From its $41 million founding round in August 2025 to achieving clinical proof-of-concept and now securing a collaboration with Roche—all within an exceptionally short timeframe—the Excalipoint team has demonstrated outstanding execution and scientific rigor.
This collaboration with Roche represents a strong endorsement from a global pharmaceutical leader of Excalipoint's differentiated TCE platform and pipeline. The combination of T cell engagers with immune checkpoint inhibitors holds the potential to unlock greater therapeutic efficacy in solid tumors.
We look forward to EXP011's continued clinical progress and its potential to deliver breakthrough treatment options for cancer patients worldwide.
Congratulations to the entire Excalipoint team!
- 上一篇：博岳生物宣布完成1.5亿元A+轮融资|凯风生态
- 下一篇：没有了